Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004016 · ClinicalTrials.gov registry record · Phase 1
Interferon Gamma in Treating Patients With Recurrent or Metastatic Melanoma or Other Solid Tumors
A Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Melanoma (Skin), sponsored by University of Rochester.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Study location
NCT00004016: Completed Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Melanoma (Skin), sponsored by University of Rochester.
NCT00004016 is a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Melanoma (Skin) that has completed, run by University of Rochester. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004016, a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Melanoma (Skin), has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Interferon gamma may interfere with the growth of cancer cells and may be an effective treatment for melanoma and solid tumors. PURPOSE: Phase I trial to study the effectiveness of interferon gamma in treating patients with recurrent or metastatic melanoma or other solid tumors.
Conditions Studied
Interventions
- BIOLOGICAL recombinant interferon gamma
Study Locations (1)
New York
- University of Rochester Cancer Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-04 |
| Phase | Phase 1 |
What the finished NCT00004016 record still lists
NCT00004016 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 2 conditions, with Unspecified Adult Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 1 intervention - of which recombinant interferon gamma is the first listed.
NCT00004016 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00004016 about?
NCT00004016 is a clinical study titled "Interferon Gamma in Treating Patients With Recurrent or Metastatic Melanoma or Other Solid Tumors". RATIONALE: Interferon gamma may interfere with the growth of cancer cells and may be an effective treatment for melanoma and solid tumors. PURPOSE: Phase I trial to study the effectiveness of interferon gamma in treating patients with recurrent or metastatic melanoma or other solid tumors.
What is the current status of trial NCT00004016?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-04.
What conditions does trial NCT00004016 study?
This clinical trial studies the following conditions: Unspecified Adult Solid Tumor, Protocol Specific, Melanoma (Skin).
What interventions are being tested in trial NCT00004016?
The interventions under investigation include: recombinant interferon gamma (BIOLOGICAL).
Who is sponsoring clinical trial NCT00004016?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00004016 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unspecified Adult Solid Tumor, Protocol Specific
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists
ACTIVE NOT RECRUITING · Phase 1
-
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
COMPLETED · Phase 1
-
Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
BMS-599626 in Treating Patients With Metastatic Solid Tumors
COMPLETED · Phase 1
-
Indole-3-Carbinol in Preventing Cancer in Healthy Participants
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia